1-(6-ethylpyridin-2-yl)-2-(quinolin-4-yl)ethan-1-one | 476472-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(6-ethylpyridin-2-yl)-2-(quinolin-4-yl)ethan-1-one
• 英文别名: 1-(6-ethyl-pyridin-2-yl)-2-quinolin-4-yl-ethanone；1-(6-Ethylpyridin-2-yl)-2-quinolin-4-ylethanone
• CAS: 476472-06-7
• 化学式: C₁₈H₁₆N₂O
• 分子量: 276.338
• InChiKey: VRJBUXDYXGHTMF-UHFFFAOYSA-N

物化性质

• 沸点：
  463.6±40.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(6-ethylpyridin-2-yl)-2-(quinolin-4-yl)ethan-1-one 在 吡啶 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[2-(6-Ethyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline
  参考文献：
  名称：

  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

  摘要：

  We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

  DOI：

  10.1016/j.bmcl.2004.04.007
• 作为产物：
  描述：

  4-甲基喹啉 、 6-乙基吡啶甲酸甲酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 1-(6-ethylpyridin-2-yl)-2-(quinolin-4-yl)ethan-1-one
  参考文献：
  名称：

  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

  摘要：

  We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

  DOI：

  10.1016/j.bmcl.2004.04.007

文献信息

• [EN] BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5<br/>[FR] DÉRIVÉS DE BENZYLAMIDE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR I/ALK5 DU FACTEUR DE CROISSANCE TRANSFORMANT BÊTA
  申请人：ORIGO BIOPHARMA S L

  公开号：WO2021105317A1

  公开（公告）日：2021-06-03

  The present invention relates to novel benzylamide derivatives of formula (I) to processes for the preparation of said compounds; to pharmaceutical compositions comprising said compounds and to said compounds for use in the treatment of pathological conditions or diseases that can improve by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as diseases and disorders associated to fibrotic conditions of gastrointestinal system, skin and eyes, to methods for the treatment and/or prevention of said diseases or pathological conditions and to combinations comprising said compounds and further comprising therapeutically effective amounts of other therapeutic agents useful for the treatment of said diseases or pathological conditions.

  本发明涉及式(I)的新型苄酰胺衍生物，以及制备该化合物的方法；包括该化合物的药物组合物，以及用于治疗可以通过抑制转化生长因子-β受体I（TGFβRI）/ALK5改善的病理状况或疾病，例如与胃肠道、皮肤和眼睛纤维化病症相关的疾病和紊乱；用于治疗和/或预防上述疾病或病理状况的方法，以及包括该化合物的组合物，进一步包括对治疗上述疾病或病理状况有用的其他治疗剂的治疗有效量。
• NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1397364B1

  公开（公告）日：2007-07-25
• PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：ELI LILLY AND COMPANY

  公开号：EP1543001B1

  公开（公告）日：2007-08-15
• Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain
  作者：J. Scott Sawyer、Douglas W. Beight、Karen S. Britt、Bryan D. Anderson、Robert M. Campbell、Theodore Goodson、David K. Herron、Hong-Yu Li、William T. McMillen、Nicholas Mort、Stephen Parsons、Edward C.R. Smith、Jill R. Wagner、Lei Yan、Faming Zhang、Jonathan M. Yingling

  DOI：10.1016/j.bmcl.2004.04.007

  日期：2004.7

  We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.